

1 **Parasite-derived circulating microRNAs as biomarkers for the detection of**
2 **human *Schistosoma japonicum* infection**

3

4 **Running title: Using circulating miRNAs for schistosomiasis diagnosis**

5 Yi Mu¹, Pengfei Cai^{1*}, Remigio M. Olveda², Allen G. Ross^{3,4}, David U. Olveda^{2,#}, Donald P.
6 McManus^{1*}

7 ¹Molecular Parasitology Laboratory, QIMR Berghofer Medical Research Institute, Brisbane,
8 Australia

9 ²Research Institute for Tropical Medicine, Department of Health, Manila, Philippines

10 ³Menzies Health Institute Queensland, Griffith University, Gold Coast, Australia

11 ⁴icddr, b, Dhaka, Bangladesh

12 # Current address: Department of Pathology, JONELTA Foundation School of Medicine,
13 University of Perpetual Help Rizal, Manila, Philippines

14

15

16 ***Correspondence:**

17 *Pengfei Cai, PhD, Molecular Parasitology Laboratory, QIMR Berghofer Medical Research
18 Institute, Tel: +61 7 3362 0405, Email: [Pengfei.Cai@qimrberghofer.edu.au](mailto: Pengfei.Cai@qimrberghofer.edu.au).

19 *Donald P. McManus, PhD, DSc, Senior Principal Research Fellow (NHMRC), Senior Scientist
20 and Head, Molecular Parasitology Laboratory, QIMR Berghofer Medical Research Institute, Tel:
21 +61 7 3362 0401, Email: [Don.McManus@qimrberghofer.edu.au](mailto: Don.McManus@qimrberghofer.edu.au).

22

23 **SUMMARY:**

24 Novel tools for early diagnosis and monitoring of schistosomiasis are urgently needed. This
25 study aimed to validate parasite-derived miRNAs as potential novel biomarkers for the detection
26 of human *Schistosoma japonicum* infection. A total of 21 miRNAs were initially validated by
27 RT-PCR using serum samples of *S. japonicum*-infected BALB/c mice. Of these, 6 miRNAs were
28 further validated with a human cohort of individuals from a schistosomiasis-endemic area of the
29 Philippines. RT-PCR analysis showed that two parasite-derived miRNAs (sja-miR-2b-5p and
30 sja-miR-2c-5p) could detect infected individuals with low infection intensity with moderate
31 sensitivity/specificity values of 66%/68% and 55%/80%, respectively. Analysis of the combined
32 data for the two parasite miRNAs revealed a specificity of 77.4% and a sensitivity of 60.0% with
33 an AUC value of 0.6906 ($p = 0.0069$); however, a duplex RT-PCR targeting both sja-miR-2b-5p
34 and sja-miR-2c-5p did not result in an increased diagnostic performance compared with the
35 singleplex assays. Furthermore, the serum level of sja-miR-2c-5p correlated significantly with
36 faecal egg counts, whereas the other five miRNAs did not. Targeting *S. japonicum*-derived
37 miRNAs in serum resulted in a moderate diagnostic performance when applied to a low
38 schistosome infection intensity setting.

39 **Keywords:**

40 Schistosomiasis; *Schistosoma japonicum*; Biomarker; Circulating miRNAs; Diagnosis;
41 Philippines

42

43 INTRODUCTION

44 Schistosomiasis, a debilitating, often fatal, disease, caused by trematode blood fluke
45 parasites of the genus *Schistosoma*, afflicts over 230 million people in 78 countries (Colley *et al.*,
46 2014). Three species of schistosomes, *Schistosoma mansoni*, *S. haematobium* and *S. japonicum*,
47 are the most clinically relevant. The zoonotic *S. japonicum* is currently endemic in P.R. China,
48 the Philippines with small foci occurring in Indonesia (Gordon *et al.*, 2019). In the Philippines, *S.*
49 *japonicum* is prevalent in 28 provinces in 12 regions of the country, with an estimated 28 million
50 individuals at risk of infection (Olveda & Gray, 2019). Currently, schistosomiasis control relies
51 predominantly on mass praziquantel (PZQ) drug administration (MDA) programs (Olveda &
52 Gray, 2019). However, MDA on its own is insufficient to provide long term sustainable control
53 of the disease if no additional integrated interventions are implemented (Mutapi *et al.*, 2017;
54 Ross *et al.*, 2015). Accurate diagnostic tools are required in the context of integrated
55 schistosomiasis control programs in the Philippines and other endemic areas.

56 Currently, three major types of diagnostic methods are available for schistosomiasis:
57 parasitological detection (e.g. the Kato-Katz (KK) test and urine filtration); serology, including
58 antibody-detection (AbD) and antigen-detection (AgD); and molecular methods (e.g., circulating
59 nucleic acids detection) (Cavalcanti *et al.*, 2013; Weerakoon *et al.*, 2015)). The different methods
60 have different advantages and disadvantages. For example, the traditional KK parasitological
61 technique shows high specificity but an insufficient level of sensitivity, particularly in areas with
62 reduced disease burden (Cai *et al.*, 2019; Oliveira *et al.*, 2018; Weerakoon *et al.*, 2015;
63 Weerakoon *et al.*, 2017b). AbD-based methods are usually cost-effective and have considerable
64 accuracy yet they have limited ability to discriminate past from active infections. Compared with
65 Ab-based detection assays, AgD-based methods, in the format of lateral flow assays targeting
66 urine samples, provide a rapid and non-invasive diagnostic, but suffer from limited sensitivity in
67 low endemic settings, a relatively high false positive rate and high cost. Molecular techniques,
68 notably polymerase chain reaction (PCR)-based-methods (Weerakoon *et al.*, 2017a; Weerakoon
69 *et al.*, 2016; Weerakoon *et al.*, 2017b)), exhibit high accuracy for the detection of schistosome
70 infections, but the current costs remain high.

71 MicroRNAs (miRNAs) are small non-coding RNAs (~22 nt), which are dysregulated in a
72 wide array of biological processes including carcinogenesis (Anvarnia *et al.*, 2019; Peng &
73 Croce, 2016). As potential targets for novel diagnosis (Li & Kowdley, 2012), circulating and/or
74 extracellular vesicle (EV)-derived miRNA signatures have been tested as biomarkers for
75 different types of diseases and disorders including cancers, infectious and inflammatory diseases
76 (Correia *et al.*, 2017; Filipów & Łaczmanski, 2019; Jamali *et al.*, 2018; Jia *et al.*, 2017;
77 Meningher *et al.*, 2017; Schonauen *et al.*, 2018; Tengda *et al.*, 2018; Xue *et al.*, 2019).
78 Circulating miRNAs also have been proposed as having potential to detect parasitic helminth
79 infections (Cai *et al.*, 2015; Dong *et al.*, 2017; Guo & Zheng, 2017; Hoy *et al.*, 2014; Tritten *et*

80 *al.*, 2014). To date, a number of parasite-derived miRNAs in plasma/serum have been validated
81 for the purpose of schistosomiasis diagnosis (Hoy *et al.*, 2014; Meninger *et al.*, 2017). However,
82 these investigations focused on the diagnosis of *S. mansoni* and *S. haematobium* infection by
83 testing a limited number of patient samples; currently there are no data on the potential of
84 detecting circulating miRNAs in individuals infected with *S. japonicum*. Recent advances in
85 characterizing miRNA profiles in extracellular vesicles secreted by *Schistosoma* species
86 (Nowacki *et al.*, 2015; Samoil *et al.*, 2018; Zhu *et al.*, 2016a; Zhu *et al.*, 2016b) have raised the
87 possibility for validating more parasite-derived miRNAs as potentially novel biomarkers for
88 schistosomiasis detection.

89 In this study, we evaluated the potential of detecting circulating parasite-derived miRNAs in
90 *S. japonicum* infected human subjects. Initially we employed the BALB/c mouse as a
91 schistosomiasis model to validate 21 parasite-derived miRNA candidates in serum during *S.*
92 *japonicum* infection. Then, following another step of screening, six candidate miRNAs were
93 selected for further validation, individually or in combination, using human sera from a cohort of
94 residents in an area in rural Philippines endemic for schistosomiasis japonica. We presented the
95 diagnostic performance of parasite-derived miRNA signatures in a *S. japonicum*-endemic setting
96 with a low-intensity infection.

97 **MATERIALS AND METHODS**

98 ***Ethics statement***

99 Animal experiments were carried out according to the Australian Code for the Care and Use of
100 Animals for Scientific Purposes (8th edition) and with the approval of the Animal Ethics
101 Committee, QIMR Berghofer Medical Research Institute (QIMRB), Brisbane, Australia (Ethics
102 Approval: Project P288). The human cohort study was approved by the Institutional Review
103 Board of the Research Institute for Tropical Medicine (RITM), Department of Health, Manila,
104 the Philippines (Approval No: 2012-13-0) and the Human Ethics Committee, QIMRB (Ethics
105 Approval: Project P524), in accordance with the Declaration of Helsinki. When conducting the
106 human study, written informed consent was obtained from all participants.

107 ***Parasites***

108 *S. japonicum*-infected *Oncomelania hupensis hupensis* snails were purchased from Nanjing
109 Municipal Center for Disease Control and Prevention, China, and transported to QIMRB,
110 Brisbane, Australia. Cercariae were shed from the infected snails under light stimulation.

111 ***Mouse infection and serum collection***

112 Three eight-week-old female BALB/c mice were percutaneously infected with a low-dose
113 challenge of *S. japonicum* cercariae (16 ± 2). Mice were sacrificed at 9 weeks p.i. and ~1 ml
114 blood was collected by cardiac puncture. Blood samples were then allowed to stand at room

115 temperature for 2 h. After centrifugation at 3,000 g for 10 min, the serum samples were collected
116 and stored at -80°C . Serum samples from three naive mice were used as controls.

117 ***Study cohort and human sample collection***

118 The human subjects were recruited from schistosomiasis-endemic areas in Laoang and
119 Palapag, Northern Samar, the Philippines. Additional information on the study population is
120 available in previous reports (Olveda *et al.*, 2017; Ross *et al.*, 2015). For each participant ~10 ml
121 blood was drawn and serum was then collected after centrifugation, and stored at $2-8^{\circ}\text{C}$. The
122 serum samples were transported to RITM, and stored at -80°C . Subsequently, a subset of
123 samples was shipped to QIMRB, Australia, on dry ice.

124 ***Parasitological detection (Kato-Katz)***

125 Each individual from the study cohort provided a stool specimen from which Kato-Katz
126 thick smear slides were prepared. Slides were examined by experienced laboratory technicians
127 under a light microscope. The burden of infection is presented as the number of eggs per gram of
128 faeces (EPG).

129 ***RNA extraction, polyadenylation and reverse transcription (RT)***

130 For each mouse, total RNA was extracted from 100 μL serum samples, and for each human
131 subject, total RNA was extracted from 200 μL serum samples, using miRNeasy mini kits
132 (Qiagen, Hilden, Germany) according to manufacturer's instructions. During the RNA extraction
133 procedure, 3.2 fmoles *Arabidopsis thaliana* ath-miR-159a (IDT, Coralville, IA) was added to
134 each sample as a spike-in control. The total RNA product was eluted with 30 μL nuclease-free
135 water.

136 A one-step procedure of polyadenylation and RT reaction was performed by the combined
137 use of two kits: a Poly(A) polymerase tailing kit (Epicentre Biotechnologies, Madison, WI) and a
138 TaqMan microRNA reverse transcription kit (Life Technologies, Carlsbad, CA). For mouse
139 samples, the Poly(A) method was used. Briefly, a 10 μL RT reaction comprised: 1 μL $10 \times$ RT
140 buffer, 1 μL ATP (10 mM), 1 μL universal RT primer (1 mM), 0.1 μL dNTPs (25 mM each), 0.13
141 μL RNase inhibitor, 0.2 μL poly(A) polymerase, 0.5 μL MultiScribe MuLV and 5 μL RNA and
142 1.07 μL nuclease-free water. Reverse transcription (RT) reactions were carried out using a Veriti
143 96-well thermal cycler (ABI, Foster City, CA) under the following condition: 37°C for 30 min,
144 42°C for 30 min, and followed by enzyme inactivation at 85°C for 5 min. For human subjects,
145 polyadenylation and RT reactions were performed using the S-Poly(T) method (Cai *et al.*, 2015).
146 The reaction system was the same as that for the Poly(A) method except that it incorporated 1 μL
147 of miRNA-specific primer pool (25 nM of each primer). RT products were stored at -20°C prior
148 to subsequent analysis. The RT primers are listed in Supplementary Table 1.

149 ***qRT-PCR for miRNA quantification***

150 Quantification of the serum levels of miRNAs was performed by probe-based qRT-PCR
151 according essentially to protocols described previously (Cai *et al.*, 2015; Cai *et al.*, 2018).
152 Briefly, the 5 μ L PCR reaction contained 2.5 μ L TaqMan Universal Master Mix II (Life
153 Technologies, Carlsbad, CA), 0.5 μ L of RT products, 1 μ L primer mixture (forward and
154 universal reverse primers) (final concentration: 0.2 μ M), 0.5 μ L universal double quenched probe
155 (final concentration: 0.25 μ M) (IDT, Coralville, IA), and 0.5 μ L nuclease-free water. The assays
156 were performed on an ABI Quantstudio 5 Real-Time PCR System (Thermo Fisher Scientific,
157 Waltham, MA) with the following cycling condition: pre-denaturation at 95°C for 10 min,
158 followed by 50 cycles: 95°C for 15 sec, and 60°C for 1 min. For analyses, a cutoff Ct value of 40
159 was set as background for the purpose of calculating signal over noise. The expression levels
160 were determined by the $2^{-\Delta\Delta C_t}$ method with the spiked-in ath-miR-159a used as the normalization
161 control. Three technical replicates were performed for each sample. The primer and probe
162 sequences used are listed in Supplementary Table 1.

163 **Statistical analysis**

164 Unpaired student's *t*-test (two tails) was used for comparing the serum levels of miRNAs in
165 naïve and *S. japonicum*-infected BALB/c mice. The Mann-Whitney *U*-test was used for analysis
166 of the capability of the serum levels of miRNAs in discriminating the KK (+) group from the
167 control group. The receiver operating characteristic (ROC) curve analyses were performed and
168 the area under the curve (AUC) was calculated to assess the potential of using the parasite-
169 derived circulating miRNAs (individually or in combination) as novel biomarkers for
170 schistosomiasis japonica. Cut-off values for determination of sensitivity and specificity were set
171 by maximizing the Youden's index. Pearson's correlation coefficient (*r*) was used for the
172 assessment of the correlation between the serum levels of miRNAs and infection intensity (egg
173 burden) in the KK (+) subjects. Statistical analysis was performed with GraphPad Prism Version
174 6.01 for windows.

175 **RESULTS**

176 ***Detection of parasite-derived miRNAs in the serum of BALB/c mice at 9 weeks post-S.*** 177 ***japonicum* infection**

178 Twenty-one miRNAs were selected to assess their potential for detection of *S. japonicum*
179 infection based on prior published studies of schistosome circulating and extracellular
180 vesicles/exosomes associated miRNAs (Supplementary Table 2). The expression of these 21
181 miRNAs was tested in naïve and *S. japonicum*-infected (9 weeks post-infection) BALB/c mice
182 by RT-PCR (Fig 1). A total of 12 miRNAs (sja-miR-277, sja-miR-3479-3p, sja-miR-125a sja-
183 miR-61, sja-miR-2b-5p, sja-miR-2162-3p, sja-miR-36-3p, sja-miR-3489, sja-miR-3487, sja-
184 miR-2c-5p, sja-miR-2a-3p and sja-miR-10) were selected for further investigation based on a
185 fold change cut-off value ≥ 4 and a *p* value cut-off < 0.05 .

186 ***Initial screening of 12 miRNAs for the diagnosis of human S. japonicum infection***

187 In the next stage of screening qRT-PCR was used to determine the expression levels of the
188 12 miRNAs selected in serum samples from KK-positive (KK (+)) patients (n = 5) and control
189 individuals (KK and SjSAP4 + Sj23-LHD-ELISA negative (Cai *et al.*, 2017)) (n = 5)
190 (Supplementary Fig 1). Receiver operating characteristic (ROC) curve analysis was performed
191 and the area under the curve (AUC) levels were calculated to evaluate the diagnostic potential of
192 each miRNA (S1 Fig). As a result, six miRNAs (sja-miRNA-277, sja-miR-125a, sja-miR-2b-5p,
193 sja-miR-36-3p, sja-miR-2c-5p and sja-miR-2a-3p) with an AUC value ≥ 0.80 were selected for
194 further validation.

195 ***The potential value of serum levels of six miRNAs by singleplex qRT-PCR for the diagnosis of***
196 ***human schistosomiasis***

197 The expression levels of sja-miRNA-277, sja-miR-125a, sja-miR-2b-5p, sja-miR-36-3p, sja-
198 miR-2c-5p and sja-miR-2a-3p were further probed using sera from a human cohort of low-
199 intensity infected individuals from a schistosomiasis-endemic area, Northern Samar, the
200 Philippines (Table 1) by qRT-PCR. The cohort included fifty-three KK (+) individuals and
201 twenty-five KK and SjSAP4 + Sj23-LHD-ELISA negatives as controls. The levels of two
202 miRNAs, sja-miR-2b-5p, and sja-miR-2c-5p, were significantly higher in patients than in control
203 individuals ($p = 0.0251$ and $p = 0.0114$, respectively), while the serum abundance of the other
204 four miRNAs, sja-miRNA-277, sja-miR-125a, sja-miR-36-3p and sja-miR-2a-3p failed to
205 differentiate the two groups ($p < 0.05$) (Fig 2A). Using optimal cut-off points, sja-miR-2b-5p and
206 sja-miR-2c-5p could detect *S. japonicum* infected individuals with a specificity/sensitivity of
207 66.0%/68.0% and 54.7%/80.0%, respectively (Fig 2A). The ROC curve analysis for the six
208 individual miRNAs in discriminating the KK (+) from the controls showed AUC values of
209 0.6340, 0.6279, 0.6574, 0.5906, 0.6770 and 0.5804 for sja-miRNA-277, sja-miR-125a, sja-miR-
210 2b-5p, sja-miR-36-3p, sja-miR-2c-5p and sja-miR-2a-3p, respectively ($p = 0.0574$, 0.0696,
211 0.0256, 0.1989, 0.0121 and 0.02542, respectively) (Fig 2B).

212 ROC curve analysis was performed to evaluate the ability of combinations of the miRNAs to
213 distinguish the KK (+) from the control participants (Table 2). Using the combined data for six
214 miRNAs, the combination of sja-miR-2b-5p and sja-miR-2c-5p was best able to differentiate
215 between the two groups with an AUC value of 0.6906 (95% CI 0.5645-0.8166; $p = 0.0069$;
216 sensitivity 77.4%, specificity 60.0%;), followed by the combination of sja-miR-125a, sja-miR-
217 2b-5p and sja-miR-2c-5p (AUC 0.6792; 95% CI 0.5541-0.8044; $p = 0.0110$; sensitivity 55.8%,
218 specificity 80.0%).

219 ***The diagnostic performance of serum miRNA levels determined by duplex and multiplex qRT-***
220 ***PCR assays for human schistosomiasis***

221 The serum miRNA levels were also probed using a duplex (designated as 2P, targeting sja-
222 miR-2b-5p and sja-miR-2c-5p) and three multiplex qRT-PCR assays with the same cohort. The

223 multiplex qRT-PCR assays were designated as 3P (targeting sja-miR-277, sja-miR-2b-5p, and
224 sja-miR-2c-5p), 5P (targeting sja-miR-125a, sja-miR-2b-5p, sja-miR-36-3p, sja-miR-2c-5p and
225 sja-miR-2a-3p) and 6P (targeting sja-miRNA-277, sja-miR-125a, sja-miR-2b-5p, sja-miR-36-3p,
226 sja-miR-2c-5p and sja-miR-2a-3p). In the 2P and 5P assays, the serum levels of targeted
227 miRNAs were significantly higher in the KK (+) than control individuals ($p = 0.0491$ and $p =$
228 0.0202 , respectively), while no significant difference was observed between the two groups in
229 the 3P and 6P assays (Fig 3A). The ROC curve analysis for discriminating the KK (+) from the
230 controls yielded AUC values of 0.6385, 0.6302, 0.6630, and 0.6185, for the 2P, 3P, 5P and 6P
231 assays, respectively ($p = 0.0495$, 0.0648 , 0.0208 and 0.0928 , respectively) (Fig 3B).

232 *Correlations of the serum miRNA levels with egg burden in the KK (+) individuals*

233 The associations between the levels of the six miRNA signatures (individually or in
234 combination) in serum and egg burden were then investigated in the KK (+) group. The serum
235 level of miRNA-2c-5p correlated with EPG ($r = 0.3222$, $p = 0.0186$), whereas the serum levels
236 of the other 5 miRNAs did not show a significant correlation with infection intensity determined
237 by the KK method (Fig 4). Also, no significant correlation was observed between the serum
238 miRNA levels determined by the duplex (2P) or multiplex assays (3P, 5P and 6P) and faecal egg
239 burden (Supplementary Fig 2).

240 **DISCUSSION**

241 Accurate diagnosis of schistosomiasis, especially in low intensity areas following MDA and
242 other control programs, remains a great challenge. Nevertheless, the development and
243 deployment of novel diagnostic tools, with the requisite accuracy, for the purpose of monitoring
244 control efforts in endemic areas to ensure schistosomiasis elimination will be critical (Cai *et al.*,
245 2017; Oliveira *et al.*, 2018; Utzinger *et al.*, 2015; Weerakoon *et al.*, 2015). The realization that
246 detection of parasite-derived miRNAs in the host circulatory system during an infection is
247 possible has generated much interest in their application as diagnostic indicators (Cai *et al.*,
248 2016a; Manzano-Roman & Siles-Lucas, 2012). The utility of using circulating miRNAs as
249 biomarkers for the detection of schistosome infections has been shown in several recent
250 pioneering investigations using animal models of schistosomiasis and/or with clinical samples
251 (Cai *et al.*, 2015; Cheng *et al.*, 2013; Hoy *et al.*, 2014; Meningher *et al.*, 2017). However, there
252 had been no reports hitherto of their use in the clinical diagnosis of schistosomiasis japonica.

253 Of the 12 initially selected miRNAs, based on results obtained in the animal model of
254 schistosomiasis japonica, the majority were unable to discriminate infected from uninfected
255 individuals in a clinical cohort (Fig 2 and Supplementary Fig 1), although an increased volume
256 of serum was used for RNA extraction from clinical samples and miRNAs extracted from human
257 samples are subjected to RT with the more sensitive S-Poly(T) method (Kang *et al.*, 2012). This

258 may have been due to the facts that: 1) the severity of a schistosome infection is far more
259 pronounced in the experimental murine model of schistosomiasis than is found in subjects who
260 are KK positive, since that even a single worm pair in a mouse represents a high infection burden
261 when body weight is taken into consideration; and 2) *S. japonicum* adult worm pairs digest a
262 considerable number of erythrocytes daily in order to obtain essential amino acids (Cai *et al.*,
263 2016b), and in so doing this results in the release of a high concentration of small RNA
264 signatures of host origin, which may readily cause non-specific amplification in the samples
265 obtained from individuals with a high burden of infection, as was the case with the BALB/c
266 mouse model utilised here.

267 Of the six miRNAs tested, any individual miRNA provided only moderate diagnostic power
268 for differentiating the KK (+) and control participants (AUC from 0.5804 to 0.6770); slightly
269 higher to the most powerful singleplex test targeting *sja-miR-2c-5p* (AUC: 0.6770, $p = 0.0121$)
270 (Fig 1), the best diagnostic performance was obtained with a combination of *sja-miR-2b-5p* and
271 *sja-miR-2c-5p* (AUC: 0.6906, $p = 0.0069$), showing a sensitivity of 76% and specificity of 60%
272 (Table 2). In order to improve the diagnostic potential by amplification two or multiple miRNAs
273 simultaneously, duplex/multiplex qRT-PCR assays were developed. The duplex assay 2P
274 targeting the two most powerful miRNA signatures (*sja-miR-2b-5p* and *sja-miR-2c-5p*) only
275 marginally discriminated the control and KK (+) individuals with an AUC of 0.6385 ($p = 0.0495$)
276 and sensitivity/specificity values of 66.0%/60.0%. The multiplex assay 3P failed to differentiate
277 the control and KK (+) subjects (AUC = 0.6302, $p = 0.0648$), while the accumulative data based
278 on singleplex assay targeting the same miRNAs exhibited moderate diagnostic power with an
279 AUC of 0.6687 ($p = 0.0168$). Furthermore, both the multiplex assay 6P and the combined data
280 based on singleplex assays targeting all six miRNAs failed to show any discrimination ability in
281 the diagnosis of clinical *S. japonicum* infections (Fig 3 and Table 2). However, the multiplex
282 assay 5P exhibited a superior diagnostic power than that obtained by the combination targeting
283 the same miRNAs (AUC 0.6630, $p = 0.0208$ vs 0.6294, $p = 0.0664$) (Fig 3 and Table 2).
284 Nevertheless, the diagnostic power of the 5P assay was inferior to that of the singleplex assay
285 detecting *sja-miR-2c-5p*. The failure of the duplex and multiplex assays to increase the
286 diagnostic power may due to: 1) The data obtained with the duplex/multiplex assays still mainly
287 depend on a highly expressed signature(s) within the target miRNAs; 2) a relatively higher noise
288 background may be introduced by targeting two or multiple targets, especially when the samples
289 from a low-intensity infection setting were tested.

290 Overall, the diagnostic performance of the assays (singleplex, duplex, and multiplex)
291 developed in the current study for detecting *S. japonicum* miRNAs in serum, was moderate, but
292 is consistent with the results obtained by Meninger *et al.* (Meninger *et al.*, 2017) when
293 detecting *S. mansoni*, *S. haematobium* and *S. mekongi* infections in twenty-six returning travelers
294 with schistosomiasis (based on the detection of eggs or the positive results of serologic tests)

295 returning from either sub-Saharan Africa or Laos by amplification of miRNAs extracted from
296 serum. Furthermore, it has been reported that parasite miRNAs are not present in plasma at a
297 sufficiently high level to be used as a biomarker for *Onchocerca volvulus* infection or for
298 monitoring treatment using miRCURY Locked Nucleic Acid (LNA) primer-based RT-qPCR
299 (Lagatie *et al.*, 2017). The modest AUC values we obtained in efforts to diagnose schistosomal
300 infections in the human Philippines cohort may be attributable to the following factors: 1) Most
301 of the KK (+) individuals tested harbored light schistosome infections (Table 1), a feature which
302 itself poses a challenge for any of the currently available diagnostic tools for schistosomiasis; 2)
303 We have previously shown that the targeted cohort is extensively co-parasitised with intestinal
304 worms and intestinal protozoa (Gordon *et al.*, 2015; Ross *et al.*, 2015; Weerakoon *et al.*, 2018).
305 These pathogens are likely to secrete RNA signatures with sequence similarity to the miRNAs
306 detected here, thereby affecting the specificity of the assays we employed; 3) The limited cohort
307 sample number may also have impaired our ability to measure elevated diagnostic scores.

308 The two most powerful serum-based signatures identified here, sja-miR-2b-5p and sja-miR-
309 2c-5p, were listed as the top fourth and fourteenth miRNAs associated with *S. japonicum* adult
310 EVs (Zhu *et al.*, 2016a), indicating that serum and serum-exosomal miRNAomes are
311 significantly different in terms of miRNA numbers, types and expression profiles (Zhao *et al.*,
312 2016). Although accumulating evidence indicates that extracellular miRNAs are mainly found
313 bound to AGO proteins (Lopez & Granados-Lopez, 2017), an active sorting mechanism of
314 exosomal miRNA may enrich specific miRNA members in extracellular vesicles/exosomes (Gon
315 *et al.*, 2017; Janas *et al.*, 2015; Villarroya-Beltri *et al.*, 2013; Zhang *et al.*, 2015). Further
316 detection of parasite-derived miRNAs from serum EV composition represents another direction
317 for the diagnosis of human *S. japonicum* infection.

318 Previously, we showed that the serum levels of two parasite-derived miRNAs, sja-miR-277
319 and sja-miR-3479-3p, exhibited a strong correlation with hepatic egg burden ($p < 0.0001$) during
320 the course of *S. japonicum* infection in C57BL/6 and BALB/c mice (Cai *et al.*, 2015). In the
321 current study, only the serum level of sja-miR-2c-5p weakly correlated with infection intensity
322 based on the KK test, indicating that the infectious status or disease progression in
323 schistosomiasis patients may be complicated. It is worth noting that the accuracy of the KK test
324 may be affected by the uneven distribution of eggs in the fecal samples and the daily fluctuation
325 in the number of eggs discharged; particular when most of the tested KK (+) individuals in the
326 cohort harbored light infections. Also, as the target cohort was located in a medium-high
327 prevalence schistosomiasis-endemic area, reinfection with *S. japonicum* was considered to be a
328 frequent occurrence. Accordingly, the abundance of parasite-derived miRNAs in the sera of re-
329 infected individuals has less chance to show a significant linear relationship with infection
330 intensity.

331 ***Concluding comments***

332 In summary, we have developed singleplex, duplex and multiplex qRT-PCR assays for the
333 diagnosis of *S. japonicum* infection by targeting parasite-derived serum miRNAs in a clinical
334 cohort from a medium-high prevalence but low infection burden schistosomiasis-endemic area.
335 The best diagnostic performance was achieved using a combination of sja-miR-2b-5p and sja-
336 miR-2c-5p (AUC: 0.6906, $p = 0.0069$). The results here shed light on the diagnostic performance
337 of parasite-derived serum miRNAs for the detection of schistosomiasis japonica by probing a
338 human cohort with low infection burden.

339

340 **ACKNOWLEDGEMENTS**

341 We thank Mary Duke for maintenance of the *S. japonicum* lifecycle at QIMRB. We also
342 appreciate the efforts of the local field and clinical staff in Palapag, Northern Samar for the
343 collection of the clinical samples.

344

345 **FINANCIAL SUPPORT**

346 This work was funded by the National Health and Medical Research Council (NHMRC) of
347 Australia (ID APP1160046, APP1037304, APP1102926 and APP1098244). D.P.M. is an
348 NHMRC Senior Principal Research Fellow and Senior Scientist at QIMRB. The funders had no
349 role in study design, data collection and analysis, decision to publish, or preparation of the
350 manuscript.

351

352 **References:**

- 353 **Anvarnia, A., Mohaddes-Gharamaleki, F., Asadi, M., Akbari, M., Yousefi, B. and**
354 **Shanehbandi, D.** (2019). Dysregulated microRNAs in colorectal carcinogenesis: New
355 insight to cell survival and apoptosis regulation. *J Cell Physiol*. doi: 10.1002/jcp.28872.
- 356 **Cai, P., Gobert, G. N. and McManus, D. P.** (2016a). MicroRNAs in parasitic helminthiasis:
357 Current status and future perspectives. *Trends Parasitol*, **32**, 71-86. doi:
358 10.1016/j.pt.2015.09.003.
- 359 **Cai, P., Gobert, G. N., You, H., Duke, M. and McManus, D. P.** (2015). Circulating miRNAs:
360 potential novel biomarkers for hepatopathology progression and diagnosis of
361 schistosomiasis japonica in two murine models. *PLoS Negl Trop Dis*, **9**, e0003965. doi:
362 10.1371/journal.pntd.0003965.
- 363 **Cai, P., Liu, S., Piao, X., Hou, N., Gobert, G. N., McManus, D. P. and Chen, Q.** (2016b).
364 Comprehensive transcriptome analysis of sex-biased expressed genes reveals discrete
365 biological and physiological features of male and female *Schistosoma japonicum*. *PLoS*
366 *Negl Trop Dis*, **10**, e0004684. doi: 10.1371/journal.pntd.0004684.
- 367 **Cai, P., Mu, Y., Olveda, R. M., Ross, A. G., Olveda, D. U. and McManus, D. P.** (2018).
368 Circulating miRNAs as footprints for liver fibrosis grading in schistosomiasis.
369 *EBioMedicine*, **37**, 334-343. doi: 10.1016/j.ebiom.2018.10.048.
- 370 **Cai, P., Weerakoon, K. G., Mu, Y., Olveda, D. U., Piao, X., Liu, S., Olveda, R. M., Chen,**
371 **Q., Ross, A. G. and McManus, D. P.** (2017). A parallel comparison of antigen
372 candidates for development of an optimized serological diagnosis of schistosomiasis
373 japonica in the Philippines. *EBioMedicine*, **24**, 237-246. doi:
374 10.1016/j.ebiom.2017.09.011.

375 **Cai, P., Weerakoon, K. G., Mu, Y., Olveda, R. M., Ross, A. G., Olveda, D. U. and**
376 **McManus, D. P.** (2019). Comparison of Kato Katz, antibody-based ELISA and droplet
377 digital PCR diagnosis of schistosomiasis japonica: Lessons learnt from a setting of low
378 infection intensity. *PLoS Negl Trop Dis*, **13**, e0007228. doi:
379 10.1371/journal.pntd.0007228.

380 **Cavalcanti, M. G., Silva, L. F., Peralta, R. H., Barreto, M. G. and Peralta, J. M.** (2013).
381 Schistosomiasis in areas of low endemicity: a new era in diagnosis. *Trends Parasitol*, **29**,
382 75-82. doi: 10.1016/j.pt.2012.11.003.

383 **Cheng, G., Luo, R., Hu, C., Cao, J. and Jin, Y.** (2013). Deep sequencing-based identification
384 of pathogen-specific microRNAs in the plasma of rabbits infected with *Schistosoma*
385 *japonicum*. *Parasitology*, **140**, 1751-1761. doi: 10.1017/S0031182013000917.

386 **Colley, D. G., Bustinduy, A. L., Secor, W. E. and King, C. H.** (2014). Human schistosomiasis.
387 *Lancet*, **383**, 2253-2264. doi: 10.1016/S0140-6736(13)61949-2.

388 **Correia, C. N., Nalpas, N. C., McLoughlin, K. E., Browne, J. A., Gordon, S. V., MacHugh,**
389 **D. E. and Shaughnessy, R. G.** (2017). Circulating microRNAs as potential biomarkers
390 of infectious disease. *Frontiers in Immunology*, **8**, 118. doi: 10.3389/fimmu.2017.00118.

391 **Dong, H., Gao, Q., Peng, X., Sun, Y., Han, T., Zhao, B., Liu, Y., Wang, C., Song, X., Wu, J.**
392 **and Yang, L.** (2017). Circulating microRNAs as potential biomarkers for veterinary
393 infectious diseases. *Front Vet Sci*, **4**, 186. doi: 10.3389/fvets.2017.00186.

394 **Filipów, S. and Łaczmanski, Ł.** (2019). Blood circulating miRNAs as cancer biomarkers for
395 diagnosis and surgical treatment response. *Frontiers in genetics*, **10**, 169-169. doi:
396 10.3389/fgene.2019.00169.

397 **Gon, Y., Maruoka, S., Inoue, T., Kuroda, K., Yamagishi, K., Kozu, Y., Shikano, S., Soda,**
398 **K., Lotvall, J. and Hashimoto, S.** (2017). Selective release of miRNAs via extracellular
399 vesicles is associated with house-dust mite allergen-induced airway inflammation. *Clin*
400 *Exp Allergy*, **47**, 1586-1598. doi: 10.1111/cea.13016.

401 **Gordon, C. A., Kurscheid, J., Williams, G. M., Clements, A. C. A., Li, Y., Zhou, X. N.,**
402 **Utzinger, J., McManus, D. P. and Gray, D. J.** (2019). Asian schistosomiasis: Current
403 status and prospects for control leading to elimination. *Trop Med Infect Dis*, **4**. doi:
404 10.3390/tropicalmed4010040.

405 **Gordon, C. A., McManus, D. P., Acosta, L. P., Olveda, R. M., Williams, G. M., Ross, A. G.,**
406 **Gray, D. J. and Gobert, G. N.** (2015). Multiplex real-time PCR monitoring of intestinal
407 helminths in humans reveals widespread polyparasitism in Northern Samar, the
408 Philippines. *Int J Parasitol*, **45**, 477-483. doi: 10.1016/j.ijpara.2015.02.011.

409 **Guo, X. and Zheng, Y.** (2017). Expression profiling of circulating miRNAs in mouse serum in
410 response to *Echinococcus multilocularis* infection. *Parasitology*, **144**, 1079-1087. doi:
411 10.1017/S0031182017000300.

412 **Hoy, A. M., Lundie, R. J., Ivens, A., Quintana, J. F., Nausch, N., Forster, T., Jones, F.,**
413 **Kabatereine, N. B., Dunne, D. W., Mutapi, F., Macdonald, A. S. and Buck, A. H.**
414 (2014). Parasite-derived microRNAs in host serum as novel biomarkers of helminth
415 infection. *PLoS Negl Trop Dis*, **8**, e2701. doi: 10.1371/journal.pntd.0002701.

416 **Jamali, L., Tofigh, R., Tutunchi, S., Panahi, G., Borhani, F., Akhavan, S.,**
417 **Nourmohammadi, P., Ghaderian, S. M. H., Rasouli, M. and Mirzaei, H.** (2018).
418 Circulating microRNAs as diagnostic and therapeutic biomarkers in gastric and
419 esophageal cancers. *J Cell Physiol*, **233**, 8538-8550. doi: 10.1002/jcp.26850.

420 **Janas, T., Janas, M. M., Sapon, K. and Janas, T.** (2015). Mechanisms of RNA loading into
421 exosomes. *FEBS Lett*, **589**, 1391-1398. doi: 10.1016/j.febslet.2015.04.036.

422 **Jia, H. L., Liu, C. W., Zhang, L., Xu, W. J., Gao, X. J., Bai, J., Xu, Y. F., Xu, M. G. and**
423 **Zhang, G.** (2017). Sets of serum exosomal microRNAs as candidate diagnostic
424 biomarkers for Kawasaki disease. *Sci Rep*, **7**, 44706. doi: 10.1038/srep44706.

425 **Kang, K., Zhang, X., Liu, H., Wang, Z., Zhong, J., Huang, Z., Peng, X., Zeng, Y., Wang, Y.,**
426 **Yang, Y., Luo, J. and Gou, D.** (2012). A novel real-time PCR assay of microRNAs
427 using S-Poly(T), a specific oligo(dT) reverse transcription primer with excellent
428 sensitivity and specificity. *PLoS One*, **7**, e48536. doi: 10.1371/journal.pone.0048536.

429 **Lagatie, O., Batsa Debrah, L., Debrah, A. and Stuyver, L. J.** (2017). Plasma-derived parasitic
430 microRNAs have insufficient concentrations to be used as diagnostic biomarker for
431 detection of *Onchocerca volvulus* infection or treatment monitoring using LNA-based
432 RT-qPCR. *Parasitol Res*, **116**, 1013-1022. doi: 10.1007/s00436-017-5382-5.

433 **Li, Y. and Kowdley, K. V.** (2012). Method for microRNA isolation from clinical serum
434 samples. *Anal Biochem*, **431**, 69-75. doi: 10.1016/j.ab.2012.09.007

435 S0003-2697(12)00454-X [pii].

436 **Lopez, J. A. and Granados-Lopez, A. J.** (2017). Future directions of extracellular vesicle-
437 associated miRNAs in metastasis. *Ann Transl Med*, **5**, 115. doi:
438 10.21037/atm.2017.01.26.

439 **Manzano-Roman, R. and Siles-Lucas, M.** (2012). MicroRNAs in parasitic diseases: potential
440 for diagnosis and targeting. *Mol Biochem Parasitol*, **186**, 81-86. doi:
441 10.1016/j.molbiopara.2012.10.001.

442 **Meningher, T., Lerman, G., Regev-Rudzki, N., Gold, D., Ben-Dov, I. Z., Sidi, Y., Avni, D.**
443 **and Schwartz, E.** (2017). Schistosomal microRNAs isolated from extracellular vesicles
444 in sera of infected patients: A new tool for diagnosis and follow-up of human
445 schistosomiasis. *J Infect Dis*, **215**, 378-386. doi: 10.1093/infdis/jiw539.

446 **Mutapi, F., Maizels, R., Fenwick, A. and Woolhouse, M.** (2017). Human schistosomiasis in
447 the post mass drug administration era. *Lancet Infect Dis*, **17**, e42-e48. doi:
448 10.1016/S1473-3099(16)30475-3.

449 **Nowacki, F. C., Swain, M. T., Klychnikov, O. I., Niazi, U., Ivens, A., Quintana, J. F.,**
450 **Hensbergen, P. J., Hokke, C. H., Buck, A. H. and Hoffmann, K. F.** (2015). Protein
451 and small non-coding RNA-enriched extracellular vesicles are released by the pathogenic
452 blood fluke *Schistosoma mansoni*. *J Extracell Vesicles*, **4**, 28665. doi:
453 10.3402/jev.v4.28665.

454 **Oliveira, W. J., Magalhaes, F. D. C., Elias, A. M. S., de Castro, V. N., Favero, V., Lindholz,**
455 **C. G., Oliveira, A. A., Barbosa, F. S., Gil, F., Gomes, M. A., Graeff-Teixeira, C.,**
456 **Enk, M. J., Coelho, P. M. Z., Carneiro, M., Negrao-Correa, D. A. and Geiger, S. M.**
457 (2018). Evaluation of diagnostic methods for the detection of intestinal schistosomiasis in
458 endemic areas with low parasite loads: Saline gradient, Helmintex, Kato-Katz and rapid
459 urine test. *PLoS Negl Trop Dis*, **12**, e0006232. doi: 10.1371/journal.pntd.0006232.

460 **Olveda, D. U., Inobaya, M., Olveda, R. M., Vinluan, M. L., Ng, S. K., Weerakoon, K.,**
461 **McManus, D. P., Ramm, G. A., Harn, D. A., Li, Y., Lam, A. K., Guevarra, J. R. and**
462 **Ross, A. G.** (2017). Diagnosing schistosomiasis-induced liver morbidity: implications for
463 global control. *Int J Infect Dis*, **54**, 138-144. doi: 10.1016/j.ijid.2016.10.024.

- 464 **Olveda, R. M. and Gray, D. J.** (2019). Schistosomiasis in the Philippines: Innovative control
465 approach is needed if elimination is the goal. *Trop Med Infect Dis*, **4**. doi:
466 10.3390/tropicalmed4020066.
- 467 **Peng, Y. and Croce, C. M.** (2016). The role of MicroRNAs in human cancer. *Signal Transduct*
468 *Target Ther*, **1**, 15004. doi: 10.1038/sigtrans.2015.4.
- 469 **Ross, A. G., Olveda, R. M., Chy, D., Olveda, D. U., Li, Y., Harn, D. A., Gray, D. J.,**
470 **McManus, D. P., Tallo, V., Chau, T. N. and Williams, G. M.** (2015). Can mass drug
471 administration lead to the sustainable control of schistosomiasis? *J Infect Dis*, **211**, 283-
472 289. doi: 10.1093/infdis/jiu416.
- 473 **Samoil, V., Dagenais, M., Ganapathy, V., Aldridge, J., Glebov, A., Jardim, A. and Ribeiro,**
474 **P.** (2018). Vesicle-based secretion in schistosomes: Analysis of protein and microRNA
475 (miRNA) content of exosome-like vesicles derived from *Schistosoma mansoni*. *Sci Rep*,
476 **8**, 3286. doi: 10.1038/s41598-018-21587-4.
- 477 **Schonauen, K., Le, N., von Arnim, U., Schulz, C., Malfertheiner, P. and Link, A.** (2018).
478 Circulating and fecal microRNAs as biomarkers for inflammatory bowel diseases.
479 *Inflamm Bowel Dis*, **24**, 1547-1557. doi: 10.1093/ibd/izy046.
- 480 **Tengda, L., Shuping, L., Mingli, G., Jie, G., Yun, L., Weiwei, Z. and Anmei, D.** (2018).
481 Serum exosomal microRNAs as potent circulating biomarkers for melanoma. *Melanoma*
482 *Res*, **28**, 295-303. doi: 10.1097/CMR.0000000000000450.
- 483 **Tritten, L., Burkman, E., Moorhead, A., Satti, M., Geary, J., Mackenzie, C. and Geary, T.**
484 (2014). Detection of circulating parasite-derived microRNAs in filarial infections. *PLoS*
485 *Negl Trop Dis*, **8**, e2971. doi: 10.1371/journal.pntd.0002971.
- 486 **Utzinger, J., Becker, S. L., van Lieshout, L., van Dam, G. J. and Knopp, S.** (2015). New
487 diagnostic tools in schistosomiasis. *Clin Microbiol Infect*, **21**, 529-542. doi:
488 10.1016/j.cmi.2015.03.014.
- 489 **Villarroya-Beltri, C., Gutierrez-Vazquez, C., Sanchez-Cabo, F., Perez-Hernandez, D.,**
490 **Vazquez, J., Martin-Cofreces, N., Martinez-Herrera, D. J., Pascual-Montano, A.,**
491 **Mittelbrunn, M. and Sanchez-Madrid, F.** (2013). Sumoylated hnRNPA2B1 controls
492 the sorting of miRNAs into exosomes through binding to specific motifs. *Nat Commun*,
493 **4**, 2980. doi: 10.1038/ncomms3980.
- 494 **Weerakoon, K. G., Gobert, G. N., Cai, P. and McManus, D. P.** (2015). Advances in the
495 Diagnosis of Human Schistosomiasis. *Clin Microbiol Rev*, **28**, 939-967. doi:
496 10.1128/CMR.00137-14.
- 497 **Weerakoon, K. G., Gordon, C. A., Cai, P., Gobert, G. N., Duke, M., Williams, G. M. and**
498 **McManus, D. P.** (2017a). A novel duplex ddPCR assay for the diagnosis of
499 schistosomiasis japonica: proof of concept in an experimental mouse model.
500 *Parasitology*, **144**, 1005-1015. doi: 10.1017/S003118201700021X.
- 501 **Weerakoon, K. G., Gordon, C. A., Gobert, G. N., Cai, P. and McManus, D. P.** (2016).
502 Optimisation of a droplet digital PCR assay for the diagnosis of *Schistosoma japonicum*
503 infection: A duplex approach with DNA binding dye chemistry. *J Microbiol Methods*,
504 **125**, 19-27. doi: 10.1016/j.mimet.2016.03.012.
- 505 **Weerakoon, K. G., Gordon, C. A., Williams, G. M., Cai, P., Gobert, G. N., Olveda, R. M.,**
506 **Ross, A. G., Olveda, D. U. and McManus, D. P.** (2017b). Droplet digital PCR diagnosis
507 of human schistosomiasis: Parasite cell-free DNA detection in diverse clinical samples. *J*
508 *Infect Dis*, **216**, 1611-1622. doi: 10.1093/infdis/jix521.

- 509 **Weerakoon, K. G., Gordon, C. A., Williams, G. M., Cai, P., Gobert, G. N., Olveda, R. M.,**
510 **Ross, A. G., Olveda, D. U. and McManus, D. P.** (2018). Co-parasitism of intestinal
511 protozoa and *Schistosoma japonicum* in a rural community in the Philippines. *Infect Dis*
512 *Poverty*, **7**, 121. doi: 10.1186/s40249-018-0504-6.
- 513 **Xue, X., Zhao, Y., Wang, X., Qin, L. and Hu, R.** (2019). Development and validation of serum
514 exosomal microRNAs as diagnostic and prognostic biomarkers for hepatocellular
515 carcinoma. *J Cell Biochem*, **120**, 135-142. doi: 10.1002/jcb.27165.
- 516 **Zhang, J., Li, S., Li, L., Li, M., Guo, C., Yao, J. and Mi, S.** (2015). Exosome and exosomal
517 microRNA: trafficking, sorting, and function. *Genomics Proteomics Bioinformatics*, **13**,
518 17-24. doi: 10.1016/j.gpb.2015.02.001.
- 519 **Zhao, K., Liang, G., Sun, X. and Guan le, L.** (2016). Comparative miRNAome analysis
520 revealed different miRNA expression profiles in bovine sera and exosomes. *BMC*
521 *Genomics*, **17**, 630. doi: 10.1186/s12864-016-2962-1.
- 522 **Zhu, L., Liu, J., Dao, J., Lu, K., Li, H., Gu, H., Liu, J., Feng, X. and Cheng, G.** (2016a).
523 Molecular characterization of *S. japonicum* exosome-like vesicles reveals their regulatory
524 roles in parasite-host interactions. *Sci Rep*, **6**, 25885. doi: 10.1038/srep25885.
- 525 **Zhu, S., Wang, S., Lin, Y., Jiang, P., Cui, X., Wang, X., Zhang, Y. and Pan, W.** (2016b).
526 Release of extracellular vesicles containing small RNAs from the eggs of *Schistosoma*
527 *japonicum*. *Parasit Vectors*, **9**, 574. doi: 10.1186/s13071-016-1845-2.

528

529 **Figure Legends**

530 **Fig 1.** The expression levels of 21 miRNAs in the sera of naïve and infected (9 wks p.i.) BALB/c
531 mice determined using qRT-PCR (Control, n = 3; 9 wks p.i., n = 3). *P* values were calculated
532 using the unpaired student's *t*-test (*, $p < 0.05$; **, $p < 0.01$; ***, $p < 0.001$).

533
534 **Fig 2.** Discrimination of *S. japonicum*-infected and non-infected individuals by detection of
535 parasite-derived miRNAs in serum. (A) The serum levels of the six candidate miRNAs in the KK
536 (+) and control subjects. Boxes represent the interquartile range of the data with lines across the
537 boxes indicate the median values. The hash marks below and above the boxes indicate the 10th
538 and 90th percentiles for each group, respectively. (B) ROC curve analysis for the six candidate
539 miRNAs was performed to evaluate the capabilities in differentiating the KK (+) and control
540 participants.

541
542 **Fig 3.** The diagnostic performance for detecting human schistosomiasis japonica using serum
543 parasite-derived miRNAs quantified by duplex and multiplex qRT-PCR assays. (A) The serum
544 levels of parasite-derived miRNA combinations in the control and KK (+) individuals. Boxes
545 represent the interquartile range of the data with lines across the boxes indicating the median
546 values. The hash marks below and above the boxes indicate the 10th and 90th percentiles for
547 each group, respectively. (B) ROC curve analysis was performed for the levels of different
548 miRNA combinations determined by the duplex and multiplex qRT-PCR assays to evaluate the
549 capabilities in discriminating the KK (+) from the control individuals.

550
551 **Fig 4.** Correlations between the serum abundance of six miRNAs and faecal egg burden (EPG)
552 in the KK (+) individuals using Pearson's correlation coefficient.

553

Table S1. Primers and probe used in this study.

	Target miRNA	Sequence (5'-3')
Universal RT primer used in the Poly(A) method		CAGTGCAGGGTCCGAGGT CAGAGCCACCTGGGCAATTTTTTTTTTTVN
	ath-miR-159a	CAGTGCAGGGTCCGAGGT CAGAGCCACCTGGGCAATTTTTTTTTTTAGAGCT
	sja-miR-277	CAGTGCAGGGTCCGAGGT CAGAGCCACCTGGGCAATTTTTTTTTTTACGGG
	sja-miR-3479-3p	CAGTGCAGGGTCCGAGGT CAGAGCCACCTGGGCAATTTTTTTTTTTCAAGGC
	sja-miR-125a	CAGTGCAGGGTCCGAGGT CAGAGCCACCTGGGCAATTTTTTTTTTTGGCAAT
	sja-miR-61	CAGTGCAGGGTCCGAGGT CAGAGCCACCTGGGCAATTTTTTTTTTTGAAGTG
	sja-miR-2b-5p	CAGTGCAGGGTCCGAGGT CAGAGCCACCTGGGCAATTTTTTTTTTTGGCTCA
RT primer pool used in the S-Poly(T) method	sja-miR-2162-3p	CAGTGCAGGGTCCGAGGT CAGAGCCACCTGGGCAATTTTTTTTTTTAGAGTG
	sja-miR-36-3p	CAGTGCAGGGTCCGAGGT CAGAGCCACCTGGGCAATTTTTTTTTTTGCGAAT
	sja-miR-3489	CAGTGCAGGGTCCGAGGT CAGAGCCACCTGGGCAATTTTTTTTTTTGCTCCT
	sja-miR-3487	CAGTGCAGGGTCCGAGGT CAGAGCCACCTGGGCAATTTTTTTTTTTGGCCA
	sja-miR-2c-5p	CAGTGCAGGGTCCGAGGT CAGAGCCACCTGGGCAATTTTTTTTTTTACATCA
	sja-miR-2a-3p	CAGTGCAGGGTCCGAGGT CAGAGCCACCTGGGCAATTTTTTTTTTTGTTTAT
	sja-miR-10	CAGTGCAGGGTCCGAGGT CAGAGCCACCTGGGCAATTTTTTTTTTTCCAAAC
	ath-miR-159a	GGTTTGATTGAAGGGAGCT
	sja-bantam	GGTGAGATCGCGATTAAAGC
	sja-miR-277	CGGTAAATGCATTTTCTGGCC
	sja-miR-3479-3p	GGTATTGCACTTACCTTCGC
	sja-miR-125b	CGGTCCCTGAGACTGATAATT
	sja-miR-125a	TGTCCCTGAGACCCTTTGAT
	sja-miR-61	GGTACTAGAAAGTGCATC
	sja-miR-2b-5p	TGCGTCTCAAAGGACTGTGA
	sja-miR-2162-3p	CGGTATTATGCAACGTTTCAC
	sja-let-7	TGGGAGGTAGTTCGTTGTGT
Forward primer used in singleplex assays	sja-miR-36-3p	TTCCACCGGGTAGACATTCA
	sja-miR-3489	TTGCCACAACAGTTTCGAGGA
	sja-miR-2d-3p	GGTATCACAGTCTGCTTAG
	sja-miR-3487	TTTCCTCGAACTGTTGTGGC
	sja-miR-2c-5p	TGACCCTTGTTTCGACTGTGA
	sja-miR-2a-3p	GGTCACAGCCAGTATTGATG
	sja-miR-71a	GGTGAAAGACGATGGTAGTG
	sja-miR-3488	TTGCTCCGGTAGCTTAGTTG
	sja-miR-3492	TGATCCGTGCTGAGATTTTCG
	sja-miR-71b-5p	CGGTGAAAGACTTGAGTAGTG
	sja-miR-307	CGGTCACAACCTACTTGATTG
	sja-miR-10	TTAACCTGTAGACCCGAGT
Forward primers used in the duplex assay 2P	sja-miR-2b-5p	TGCGTCTCAAAGGACTGTGA
	sja-miR-2c-5p	TGACCCTTGTTTCGACTGTGA
Forward primers used in the multiplex assay 3P	sja-miR-2b-5p	TGCGTCTCAAAGGACTGTGA
	sja-miR-36-3p	TTCCACCGGGTAGACATTCA
	sja-miR-2c-5p	TGACCCTTGTTTCGACTGTGA
Forward primers used in the multiplex assay 5P	sja-miR-125a	TGTCCCTGAGACCCTTTGAT
	sja-miR-2b-5p	TGCGTCTCAAAGGACTGTGA
	sja-miR-36-3p	TTCCACCGGGTAGACATTCA
	sja-miR-2c-5p	TGACCCTTGTTTCGACTGTGA
	sja-miR-2a-3p	GGTCACAGCCAGTATTGATG
Forward primers used in the multiplex assay 6P	sja-miR-277	CGGTAAATGCATTTTCTGGCC
	sja-miR-125a	TGTCCCTGAGACCCTTTGAT
	sja-miR-2b-5p	TGCGTCTCAAAGGACTGTGA
	sja-miR-36-3p	TTCCACCGGGTAGACATTCA
	sja-miR-2c-5p	TGACCCTTGTTTCGACTGTGA
	sja-miR-2a-3p	GGTCACAGCCAGTATTGATG
Universal reverse primer		CAGTGCAGGGTCCGAGGT
Universal double-quenched probe		56-FAM/CAGAGCCAC/ZEN/CTGGGCAATTT/3IABkFQ



Table S2. Twenty-one miRNAs selected based on published studies of schistosome circulating and extracellular vesicles/exosomes associated miRNAs

miRNA	Sequence[#]	Ref
bantam	UGAGAUCGCGAUUAAAGCUGGU	[1-7]
miR-277	UAAAUGCAUUUUCUGGCCCGU	[1, 2, 4, 6, 8]
miR-3479-3p	UAUUGCACUUACCUUCGCCUUG	[4, 6-8]
miR-125b	UCCCUGAGACUGAUAAUUGCUC	[1-3]
miR-125a	UCCCUGAGACCCUUUGAUUGCC	[3]
miR-61	UGACUAGAAAGUGCACUCACUUC	[1-3, 6]
miR-2b-5p	CGUCUCAAAAGGACUGUGAGCC	[1]
miR-2162-3p	UAUU AUGCAACGUUUCACUCU	[3, 4, 6]
let-7	GGAGGUAGUUCGUUGUGUGGU	[1]
miR-36-3p	CCACCGGGUAGACAUUCAUUCGC	[1, 2, 6]
miR-3489	GCCACAACAGUUCGAGGACG	[1]
miR-2d-3p	UAUCACAGUCCUGCUUAGGUGACG	[1, 6]
miR-3487	UCCUCGAACUGUUGUGGCC	[1]
miR-2c-5p	ACCCUUGUUCGACUGUGAUGU	[1, 2]
miR-2a-3p	UCACAGCCAGU AUUGAUGAAC	[2, 4, 6]
miR-71a	UGAAAGACGAUGGUAGUGAGAUG	[1-3, 6]
miR-3488	GCUCCGGUAGCUUAGUUGGU	[2, 5]
miR-3492	AUCCGUGCUGAGAUUUCGUCU	[2, 3]
miR-71b-5p	UGAAAGACUUGAGUAGUGAGACG	[2, 3]
miR-307	UCACAACCUACUUGAUUGAGGGG	[6]
miR-10-5p	AACCCUGUAGACCCGAGUUUGG	[1-4, 7]





[#] *S. japonicum* miRNA sequences are shown

1. Zhu L, Liu J, Dao J, Lu K, Li H, Gu H, et al. Molecular characterization of *S. japonicum* exosome-like vesicles reveals their regulatory roles in parasite-host interactions. *Sci Rep.* 2016;6:25885.
2. Nowacki FC, Swain MT, Klychnikov OI, Niazi U, Ivens A, Quintana JF, et al. Protein and small non-coding RNA-enriched extracellular vesicles are released by the pathogenic blood fluke *Schistosoma mansoni*. *J Extracell Vesicles.* 2015;4:28665.
3. Samoil V, Dagenais M, Ganapathy V, Aldridge J, Glebov A, Jardim A, et al. Vesicle-based secretion in schistosomes: Analysis of protein and microRNA (miRNA) content of exosome-like vesicles derived from *Schistosoma mansoni*. *Sci Rep.* 2018;8(1):3286.
4. Hoy AM, Lundie RJ, Ivens A, Quintana JF, Nausch N, Forster T, et al. Parasite-derived microRNAs in host serum as novel biomarkers of helminth infection. *PLoS Negl Trop Dis.* 2014;8(2):e2701.
5. Meninger T, Lerman G, Regev-Rudzki N, Gold D, Ben-Dov IZ, Sidi Y, et al. Schistosomal microRNAs isolated from extracellular vesicles in sera of infected patients: A new tool for diagnosis and follow-up of human schistosomiasis. *J Infect Dis.* 2017;215(3):378-86.

6. Zhu S, Wang S, Lin Y, Jiang P, Cui X, Wang X, et al. Release of extracellular vesicles containing small RNAs from the eggs of *Schistosoma japonicum*. *Parasit Vectors*. 2016;9(1):574.
7. Cheng G, Luo R, Hu C, Cao J, Jin Y. Deep sequencing-based identification of pathogen-specific microRNAs in the plasma of rabbits infected with *Schistosoma japonicum*. *Parasitology*. 2013;140(14):1751-61.
8. Cai P, Gobert GN, You H, Duke M, McManus DP. Circulating miRNAs: potential novel biomarkers for hepatopathology progression and diagnosis of schistosomiasis japonica in two murine models. *PLoS Negl Trop Dis*. 2015;9(7):e0003965.

A**B**

Eggs per gram of faeces
(log₁₀)



Relative expression